OncoMatch/Clinical Trials/NCT06508463
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Is NCT06508463 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter and Cemiplimab for peripheral t cell lymphoma.
Treatment: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter · Cemiplimab · Ipilimumab — This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
Relapsed or refractory
Cannot have received: IMIDs
Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) ≤ 2 weeks prior to registration
Cannot have received: alkylating agent
Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) ≤ 2 weeks prior to registration
Cannot have received: proteasome inhibitor
Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) ≤ 2 weeks prior to registration
Cannot have received: monoclonal antibody
Immunotherapy (monoclonal antibodies) ≤ 4 weeks prior to registration
Cannot have received: experimental agent
Experimental agent in case of Acute Myeloid Leukemia (AML) or TCL within 4 half-lives of the last dose of the agent
Lab requirements
Blood counts
ANC ≥ 1,000/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 8.5 g/dl
Kidney function
Creatinine ≤ 2.0 mg/dL
Liver function
ALT and AST ≤ 2 x ULN; Direct bilirubin ≤ 1.5 x ULN; If baseline liver disease, Child Pugh score not exceeding class A
ALT and AST ≤ 2 x ULN; Direct bilirubin ≤ 1.5 x ULN; Creatinine ≤ 2.0 mg/dL; INR/PT and aPTT ≤ 1.5 x ULN; If baseline liver disease, Child Pugh score not exceeding class A; ANC ≥ 1,000/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 8.5 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify